Aquit
case study
Immunostimulants for aquiculture
Pre-Seed
Chile
Buenos Aires, Argentina

What's the Problem?

Aquaculture industry's annual growth rate of 6% is projected to generate profits exceeding USD 208.9 billion by 2025. Despite the increased impact of this industry on food production, serious threats to its economic growth have emerged due to various diseases that attack farmed fish, resulting in losses of over USD 6 billion per year. To combat infection outbreaks, the industry spends an additional billion on ineffective vaccines and large amounts of antibiotics with disastrous effects on the environment and our health. Nevertheless, antibiotic consumption is expected to increase by 33% by 2030. For instance, in 2021, Chile, the second-largest salmon producer worldwide, had returns exceeding 5 billion USD. The Chilean salmon farming industry uses resources that are deemed ineffective in controlling pathogen outbreaks during the production cycle. Despite these measures, economic losses attributed to infections exceed 500 million USD, and producers continue to lose key markets due to more stringent regulations on antibiotics. There is an urgent need to develop new technologies to cope with infectious diseases in aquaculture.

Aquit
Aquit
Aquit
Aquit

How are they Solving it?

AQUIT developed a disruptive and cost-effective technology that improves survival rates for fish and replaces antibiotics. The focus was on reinforcing the fish immune system using a recombinant protein. How was this achieved? AQUIT identified and selected the key protein from the salmon that's essential for activating its immunity. The gene sequence was optimized and engineered, and, with the use of safe microorganisms in bioreactors, AQUIT produced this protein at scale.

Eywa

Next Startup

Eywa